Cyprium Therapeutics, a subsidiary of Fortress Biotech, has had its New Drug Application for CUTX-101 accepted for priority review by the FDA, with a decision expected by June 30, 2025; Cyprium will receive royalties and up to $129 million in milestones from Sentynl, which is handling commercialization.